Obesity remains a pressing global health issue, increasing the risk of diabetes, heart disease, and other metabolic conditions. While lifestyle and environment are crucial, scientists are probing how specific nutrients like dietary fat directly influence the brain’s control of appetite and body weight.
Recent research has turned to the hypothalamus, a brain region that helps regulate hunger and energy balance. Within this area, certain neurons are known to respond to hormones and nutrients, but the molecular machinery that links fatty foods to overeating has been less clear.
How a mitochondrial protein shapes appetite
A team led by Professor Shigenobu Matsumura at Osaka Metropolitan University examined a protein called optic atrophy 1, or OPA1. This protein supports mitochondrial fusion and function inside hypothalamic MC4R neurons, which are key players in appetite suppression and energy expenditure.
To test OPA1’s role, researchers compared normal mice with genetically modified animals lacking OPA1 specifically in MC4R neurons. All mice were allowed free access to soybean oil, a common source of dietary fat, to see how this would alter eating patterns, weight gain, and metabolic health over time.
High fat intake affects sexes differently
The study found that soybean oil boosted OPA1 expression in male wild-type mice, but this response was not observed in females. This suggests that male and female brains may adapt differently to fatty foods at the mitochondrial level, even before visible changes in weight occur.
Mice missing OPA1 in MC4R neurons consumed more food overall, accumulated excess weight with age, and ultimately developed obesity. When given a choice between standard chow and soybean oil, these OPA1-deficient mice favored the high fat option and gained additional weight, with the effect especially pronounced in females.
Anti-obesity drug shows uneven benefits
The team also evaluated setmelanotide, an MC4R agonist already approved for certain rare genetic forms of obesity. In male control mice and males lacking OPA1, the drug effectively reduced food intake, indicating that MC4R signaling can still curb appetite despite disrupted mitochondrial fusion.
In females without OPA1, however, setmelanotide’s appetite-suppressing effect was markedly weaker. This sex-specific difference suggests that intact mitochondrial dynamics in MC4R neurons may be more critical for the drug’s action in female brains than in male ones.
Implications for personalized obesity treatment
Professor Matsumura said the findings highlight how neuronal energy metabolism can shape obesity risk and drug response. The observed sex differences in OPA1 regulation and obesity susceptibility point to the need for therapies that account for biological sex when targeting brain pathways that control appetite.
The study adds to a growing body of evidence that mitochondrial health in hypothalamic neurons influences weight regulation. As new obesity treatments emerge, including GLP-1 receptor agonists and MC4R-targeting drugs, understanding these cellular mechanisms could help tailor more effective, personalized interventions.
The research was published in the FASEB Journal and complements broader work showing that high fat diets can alter brain inflammation, hormone signaling, and mitochondrial function. Further studies in humans will be needed to confirm how OPA1 and related pathways contribute to overeating and differential drug responses across sexes.